argenx NV ADR (ARGX)vsCureVac NV (CVAC)
ARGX
argenx NV ADR
$891.76
+1.05%
HEALTHCARE · Cap: $54.94B
CVAC
CureVac NV
$4.66
0.00%
HEALTHCARE · Cap: $1.05B
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 8262% more annual revenue ($5.92B vs $70.74M). CVAC leads profitability with a 182.1% profit margin vs 31.7%. CVAC trades at a lower P/E of 7.0x. ARGX earns a higher WallStSmart Score of 73/100 (B).
ARGX
Strong Buy73
out of 100
Grade: B
CVAC
Buy56
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+67.5%
Fair Value
$2566.94
Current Price
$891.76
$1675.18 discount
Margin of Safety
+61.5%
Fair Value
$12.10
Current Price
$4.66
$7.44 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 31 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 36.3%
Revenue surging 52.1% year-over-year
Earnings expanding 50.6% YoY
Conservative balance sheet, low leverage
Attractively priced relative to earnings
Reasonable price relative to book value
Keeps 182 of every $100 in revenue as profit
Strong operational efficiency at 573.0%
Safe zone — low bankruptcy risk
Every $100 of equity generates 22 in profit
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 165.8x book value
Smaller company, higher risk/reward
Revenue declined 89.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 31.7% and operating margin at 36.3%. Revenue growth of 52.1% demonstrates continued momentum.
Bull Case : CVAC
The strongest argument for CVAC centers on P/E Ratio, Price/Book, Profit Margin. Profitability is solid with margins at 182.1% and operating margin at 573.0%.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Bear Case : CVAC
The primary concerns for CVAC are Market Cap, Revenue Growth.
Key Dynamics to Monitor
ARGX profiles as a growth stock while CVAC is a declining play — different risk/reward profiles.
CVAC carries more volatility with a beta of 1.84 — expect wider price swings.
ARGX is growing revenue faster at 52.1% — sustainability is the question.
ARGX generates stronger free cash flow (749M), providing more financial flexibility.
Bottom Line
ARGX scores higher overall (73/100 vs 56/100), backed by strong 31.7% margins and 52.1% revenue growth. CVAC offers better value entry with a 61.5% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
CureVac NV
HEALTHCARE · BIOTECHNOLOGY · USA
CureVac NV, a clinical-stage biopharmaceutical company, is focused on developing various transformative drugs based on messenger ribonucleic acid (mRNA). The company is headquartered in Tbingen, Germany.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?